PROGEN Share Price Performance
SEK 0.69
-12.81 (-94.86%)
Price SEK 0.69
Share PriceSEK 0.69
Prostatype Genomics AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
PROGEN Community Narratives
There are no narratives available yet.
Recent PROGEN News & Updates
Prostatype Genomics AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 12, 2026
- Earnings per share (EPS)
- -1.22
- Gross Margin
- -2,948.25%
- Net Profit Margin
- -6,336.50%
- Debt/Equity Ratio
- 0%
Prostatype Genomics AB (publ) Competitors
Snowflake Analysis
About PROGEN
- Founded
- 2007
- Employees
- 6
- CEO
- WebsiteView website
Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Swedish Market Performance
- 7 Days: 0.8%
- 3 Months: 2.3%
- 1 Year: 0.5%
- Year to Date: 3.3%
In the last week, the market has been flat, with a notable exception in the Energy sector dropping 3.8%. In line with that, the market has also been flat over the past year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›